Author

c. E. badr

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Alnasser· 1 shared A. E. Nibbs· 1 shared A. Kirov· 1 shared A. Sammarco· 1 shared B. A. Tannous· 1 shared B. Su· 1 shared C. C. da Hora· 1 shared C. Moses· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Alnasser

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Divergent MEK/ERK and AMPK signaling dictate lipogenic plasticity and dependence on fatty acid synthesis in Glioblastoma

K. Eyme, A. Sammarco, R. Jha, H. MNATSAKANYAN, R. Neustadt, C. Moses, A. Alnasser, D. Tardiff, B. Su, K. Williams, S. Bensinger, C. Y. Chung, c. E. badr

This study identifies that MEK/ERK and AMPK signaling regulate lipogenic plasticity in Glioblastoma stem-like cells, influencing their dependence on fatty acid synthesis and response to DNLS inhibitors.

bioRxiv · Apr 7, 2022 · PreprintCancer Biology

Obtusaquinone is a cysteine modifying compound that targets Keap1 for degradation

c. E. badr, C. C. da Hora, A. Kirov, R. Amante, E. Fitzsimons, J. W. Chen, A. E. Nibbs, I. Nakano, E. Tabet, N. Chiu, W. Haas, R. Mazitschek, B. A. Tannous

This study identifies Obtusaquinone as a cysteine-modifying compound that targets Keap1 for degradation, activating the Nrf2 pathway through proteasomal degradation.

ACS Chemical Biology · Apr 27, 2020Peer-reviewedCancer Biology